Try our Advanced Search for more refined results

MiraLAX Generics Get FDA Reprieve Despite Bayer Objections

By Jeff Overley ( April 20, 2018, 7:13 PM EDT) -- Sales of generic versions of popular constipation drug MiraLAX will be allowed for an extra six months, the U.S. Food and Drug Administration revealed Friday, rejecting opposition from Bayer AG and reversing the agency's own recent order requiring sales to end promptly....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections

Law Firms

Companies

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!